Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Amortization - GoodwillCost of RevenueEBIATGross ProfitReceivables - NetRent ExpenseWages, Salaries and Other
Ratios

Avricore Health (AVCRF) Cost of Revenue (2016 - 2025)

Avricore Health has reported Cost of Revenue over the past 11 years, most recently at $29227.0 for Q4 2025.

  • Quarterly Cost of Revenue fell 95.09% to $29227.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $211409.9 through Dec 2025, down 90.03% year-over-year, with the annual reading at $211559.4 for FY2025, 90.03% down from the prior year.
  • Cost of Revenue was $29227.0 for Q4 2025 at Avricore Health, down from $65600.6 in the prior quarter.
  • Over five years, Cost of Revenue peaked at $626512.5 in Q4 2023 and troughed at $4683.7 in Q1 2021.
  • The 5-year median for Cost of Revenue is $165369.4 (2023), against an average of $254142.7.
  • Year-over-year, Cost of Revenue skyrocketed 2801.41% in 2022 and then plummeted 95.09% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $20526.0 in 2021, then skyrocketed by 2801.41% to $595543.3 in 2022, then grew by 5.2% to $626512.5 in 2023, then fell by 5.03% to $594975.1 in 2024, then plummeted by 95.09% to $29227.0 in 2025.
  • Per Business Quant, the three most recent readings for AVCRF's Cost of Revenue are $29227.0 (Q4 2025), $65600.6 (Q3 2025), and $55418.1 (Q2 2025).